Back to search results

Predicting Chemotherapy Response in Pancreatic Cancer

This study is looking for a better way to predict how well people with pancreatic cancer will respond to chemotherapy given before surgery (neoadjuvant chemotherapy). Researchers are studying pre-treatment blood samples to find tiny genetic markers called microRNAs. They will use these markers to develop a test, called the PRECEPT assay, that could help doctors understand if treatments like FOLFIRINOX or gemcitabine/nab-paclitaxel will be effective for you. The goal is to improve treatment choices for patients. This study is currently unclear about its status and plans to include 200 participants. You may be able to join if you have pancreatic ductal adenocarcinoma, received neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel), had surgery to remove the cancer, and have pre-treatment plasma samples available.

Study design
This is an observational study, meaning researchers will look at existing information and samples. It aims to include 200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure how well the treatment worked for up to one year after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07226154

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~200 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Small RNA sequencingPRECEPT assay (qRT-PCR validation)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pathological Response Rate
Measured over up to 1 year

Conditions

Pancreatic Ductal Adenocarcinoma

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT07226154

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Ajay Goel, PhD
[email protected]
626-218-3452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
Availability of pre-treatment plasma samples.
Underwent curative-intent resection (R0 or R1).

Exclusion

Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
Non-adenocarcinoma histology.
Presence of synchronous or multiple primary malignancies.
Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
Presence of active inflammatory or autoimmune diseases.

What this trial measures

  • Pathological Response Rateup to 1 year

    Proportion of patients achieving partial or complete pathologic response after neoadjuvant chemotherapy, as assessed using resected pancreatic cancer specimens.